Mabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311

Stock News

06/23

Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.

The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.

6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1178147278"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178147278\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178147278?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178147278","market":"sh","top_or_hot":-1,"title":"Mabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311","media":"Stock News","content":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.<br><br>The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.<br><br>6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell Bioscience Receives Regulatory Clearance to Initiate Human Trials for Investigational Drug 6MW5311\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-06-23 18:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.<br><br>The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.<br><br>6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.<br><br></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688062","symbol_name":"邁威生物-U","start_time":0,"source_url":"","article_id":"1178147278","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178147278","pubTimestamp":1782211223,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.The approval pertains to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物-U","BK0239":"医药制造","BK1161":"生物科技","02493":"迈威生物-B"},"translate_title":"Mabwell Bioscience获得监管部门批准启动研究药物6MW5311人体试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"02493":1},"content_text":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it has received a clinical trial approval notice from the National Medical Products Administration.The approval pertains to the investigational new drug application for 6MW5311 injection, intended for the treatment of hematologic malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.6MW5311 is a bispecific antibody targeting LILRB4 and CD3, developed utilizing the company's T Cell Engager technology platform, and is being developed for these specific blood cancer indications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}